'Deadly Risk' of Fat-Loss Drugs
Newsweek Europe|March 22, 2024
Diabetes treatment Ozempic has become popular among dieters due to its weightloss side effect, but a study warns of a link between the drug and suicidal thoughts
PANDORA DEWAN
'Deadly Risk' of Fat-Loss Drugs

"MIRACLE" FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned.

The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2 diabetes, but it has gained popularity and gone viral on social media due to one sought-after side effect: weight loss.

Ozempic is based on a naturally occurring human hormone called glucagon-like peptide 1, which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.

In doing so, semaglutide induces feelings of fullness while delaying the emptying of our stomach, making us less hungry and therefore less likely to overeat.

Semaglutide is also used in Ozempic's sister drug, Wegovy, which has been approved by the FDA for chronic weight management. Between the start of 2020 and the end of 2022, prescriptions of GLP-1 mimic medications like semaglutide increased by 300 percent across the U.S., according to health care analytics firm Trilliant Health.

The drug has since been endorsed by celebrities and influencers, with #ozempic reaching over 1.4 billion views on TikTok. However, when used as a weight-loss drug, semaglutide has been shown to have some uncomfortable side effects.

Most studies into these have focused on gut problems, but a new study, published in the International Journal of Clinical Pharmacy, has highlighted a concerning association between semaglutide and adverse psychiatric events, including depression, anxiety and suicidal thoughts. Pharmaceutical manufacturer Novo Nordisk, which produces Ozempic and Wegovy, cited the FDA saying that no evidence was found regarding suicidal thoughts or actions caused by these medicines.

Denne historien er fra March 22, 2024-utgaven av Newsweek Europe.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra March 22, 2024-utgaven av Newsweek Europe.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA NEWSWEEK EUROPESe alt
Mystery of Ginger Cat Is out of the Bag
Newsweek Europe

Mystery of Ginger Cat Is out of the Bag

The genetics behind the vibrant orange color in feline coats is finally confirmed after 112 years

time-read
3 mins  |
January 03-17, 2025 (Double Issue)
Paris Hilton & Nicole Richie
Newsweek Europe

Paris Hilton & Nicole Richie

PARIS HILTON AND NICOLE RICHIE ARE READY TO BRING A LITTLE “SANASA” to the world with Peacock's Paris & Nicole: The Encore, their first project together since their reality show The Simple Life ended in 2007. What's “sanasa”? It's a song and phrase the longtime friends created as kids and popularized on The Simple Life. The show, a cultural phenomenon in the early days of reality TV, followed them over a series of blue-collar jobs. Now they're bringing it back as an opera. “I know this is just going to make people laugh, have fun, be nostalgic and just celebrate our friendship,” Hilton said. While Richie acknowledged “you can't do Simple Life again,” she said now “felt like the right time.” The famous pair also revisit some old jobs in Arkansas, like fast-food chain Sonic, where they now have drinks named for them. “I think that there is a part of our friend- ship that the show ended up showing that people connect to,” Richie said. As for this new special, Hilton is glad to do something positive for their fans. “It's been such a crazy past couple years, and I just feel like the world needs more joy.”

time-read
2 mins  |
January 03-17, 2025 (Double Issue)
What Next for Your Drugstore?
Newsweek Europe

What Next for Your Drugstore?

Walgreens and Amazon are placing opposing bets on the future of retail pharmacy

time-read
6 mins  |
January 03-17, 2025 (Double Issue)
AMERICA'S GREATEST WORKPLACES for Diversity
Newsweek Europe

AMERICA'S GREATEST WORKPLACES for Diversity

AS COMPANIES IN THE UNITED STATES CONTINUE TO navigate the evolving dynamics of the workplace, diversity remains a cornerstone of organizational success and social responsibility.

time-read
4 mins  |
January 03-17, 2025 (Double Issue)
FIGHTING SPIRITS
Newsweek Europe

FIGHTING SPIRITS

ANDREA MCCARTHY TOLD FRIENDS and family when she gave up alcohol on January 1, 2024, that she would toast 12 months off the sauce with a drink to ring in 2025. As that anniversary approached, the Los Angeles-born content creator told Newsweek she had had a change of heart.

time-read
10 mins  |
January 03-17, 2025 (Double Issue)
Lessons Over Lunch
Newsweek Europe

Lessons Over Lunch

Ninety-year-old volunteer Hugh showed me how the winter years can be full of purpose

time-read
3 mins  |
January 03-17, 2025 (Double Issue)
Is California's Green Dream Hot Air?
Newsweek Europe

Is California's Green Dream Hot Air?

The state aims to rely on zero-carbon energy sources in two decades' time but has hurdles to overcome along the way

time-read
8 mins  |
January 03-17, 2025 (Double Issue)
Power Struggle
Newsweek Europe

Power Struggle

As the dust settles following the toppling of Bashar al-Assad, new front lines could be drawn in Syria's old civil war

time-read
6 mins  |
January 03-17, 2025 (Double Issue)
Ray Romano
Newsweek Europe

Ray Romano

THE MAJOR THING ABOUT NETFLIX'S NO GOOD DEED THAT APPEALED TO Ray Romano was that it was unlike anything he'd done before.

time-read
2 mins  |
December 27, 2024
Has J.K. Rowling Won the Culture War?
Newsweek Europe

Has J.K. Rowling Won the Culture War?

After years of backlash over trans issues, the Harry Potter author has received major business backing

time-read
7 mins  |
December 27, 2024